Nature Communications (Mar 2020)

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma

  • Richa Bajpai,
  • Aditi Sharma,
  • Abhinav Achreja,
  • Claudia L. Edgar,
  • Changyong Wei,
  • Arusha A. Siddiqa,
  • Vikas A. Gupta,
  • Shannon M. Matulis,
  • Samuel K. McBrayer,
  • Anjali Mittal,
  • Manali Rupji,
  • Benjamin G. Barwick,
  • Sagar Lonial,
  • Ajay K. Nooka,
  • Lawrence H. Boise,
  • Deepak Nagrath,
  • Mala Shanmugam

DOI
https://doi.org/10.1038/s41467-020-15051-z
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 16

Abstract

Read online

Venetoclax monotherapy is effective in 40% of t(11:14) positive multiple myeloma (MM). Here, the authors show that electron transport chain complex I (CI) and complex II (CII) activity predict MM sensitivity to venetoclax, and inhibition of CI with IACS-010759 or CII with TTFA increase sensitivity.